

Implementation Partner Program



-

Antimicrobial Resistance In the News



Kelly Burch Jan 19, 2021, 8:37 AM



Overuse contributes to dangerous drug-resistant bacteria

by Kristina Sauerwein . January 28, 2020

'superbug' infections in kids

f (1) (...)



Antimicrobial resistance hurting global war against Covid-19: **Chandigarh doctors**

National and Global Health Support



More than 2.8 million antibiotic-resistant infections occur in the United States each year, and more than 35,000 people die as a result.

Antibiotic Resistance Threats in the United States 2019, CDC




WHO has declared that AMR is one of the top 10 global public health threats facing humanity.

Antimicrobial Resistance Key facts, 13 October 2020, World Health Organization (WHO)

Antimicrobial Resistance: Simplified

- ✓ Antibiotics are common treatment for infections
- ✓ Inappropriate antibiotics prescribing causes resistance
- ✓ Global health issue
- ✓ Solvable: Takes discipline to manage antibiotics therapy
- ✓ Information systems can help in the hospital setting



Opportunity for Information Systems

CDC strategies that work in healthcare:



Preventing device- and procedurerelated infections, such as from urinary catheters or central lines



Stopping the spread of resistant germs within and between healthcare facilities



Containing emerging threats through early detection and aggressive response




Tracking and improving appropriate antibiotic use



Infection prevention and control in non-hospital settings, such as long-term care facilities

Antibiotic Rx for Hospitals

Proceed with Caution



SOURCE: CDC Vital Signs. March 2014. www.cdc.gov/vitalsigns.

Established Guidelines

CDC



Hospital Leadership Commitment

Dedicate necessary human, financial, and information technology resources.



Accountability

Appoint a leader or co-leaders, such as a physician and pharmacist, responsible for program management and outcomes.



Pharmacy Expertise (previously "Drug Expertise"):

Appoint a pharmacist, ideally as the co-leader of the stewardship program, to help lead implementation efforts to improve antibiotic use.



Action

Implement interventions, such as prospective audit and feedback or preauthorization, to improve antibiotic use.



Tracking

Monitor and other important outcomes, like *C. difficile* infections and resistance patterns.



Reporting

Regularly for information on antibiotic use and resistance to prescribers, pharmacists, nurses, and hospital leadership.



Education

Educate processory ers, pharmacists, nurses, and patients about adverse reactions from antibiotics, antibiotic resistance, and optimal prescribing.

WHO



https://apps.who.int/iris/bitstream/handle/10665/329404/9789241515481-eng.pdf

Target Hospital Audience

- Antimicrobial Stewardship Team Leaders
- Hospital Infectious Disease Physicians






Using MEDICI to follow ASP Best Practice: CDC Core Elements




Implement interventions






Monitor medication orders for continued appropriateness







Report on antibiotic use and resistance patterns




MEDICI® Cloud Architecture






Data Elements

- Hospital Encounters
- Patient Demographics
- Medication Orders
- Lab Results
- Microbiology Tests
- Allergies
- Diagnoses









NHSN CDA Submission Support Portal (CSSP)

Vendors that have Passed the AU SDS Validation



Beginning in January 2020, NHSN will list vendors that have passed Antimicrobial Use Synthetic Data Set (AU SDS) Validation below:

As a vendor neutral, federal program, NHSN does not endorse any AU CDA vendors. Rather the list below will inform current and prospective customers of vendor services and successes with respect to the NHSN AU Option SDS validation. It may take up to two months for this webpage to be updated with passing vendor information.




Please refer to the <u>AU Synthetic Data Set Validation</u> website for information describing the AU SDS, the validation process, and FAQs.



Vendor Name	Vendor Software	Software Version/ Release	Date Passed Validation
Asolva, Inc [2	Medici	3	1/15/2020
Asolva, Inc ☐	Medici	5	2/19/2020

Asolva's Commitment to ASP



Asolva, Inc. (California, U.S.)

Having served as IT professionals in healthcare for nearly 20 years, Asolva, Inc. commits to work with public health agencies to enable antibiotic use reporting at any health care facility regardless of size, geography, infrastructure, and resources. Asolva aims to partner with state health departments to expand antibiotic use reporting to CDC's National Healthcare Safety Network with the use of their reporting technology that will work with any hospital for a low cost.

https://www.cdc.gov/drugresistance/intl-activities/amr-challenge.html

Using Synthetic Data to Enhance Antimicrobial Use Data Quality within the National Healthcare Safety Network

Wendy L. Wise, MPH, PMP^{1,2}; Senthil K. Nachimuthu, MD, PhD, FAMIA^{3,4}; Joseph Chuong, MS⁵; Jay P Kim, RPh, MBA⁶; Shuai Zheng, PhD¹

¹Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA; ²Lantana Consulting Group, East Thetford, VT; ³IDEAS Center, VA Salt Lake City Healthcare System, Salt Lake City, UT; ⁴Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT; ⁵Asolva, Pasadena, CA; ⁶Cerner Corporation, Kansas City, MO

Abstract

The Centers for Disease Control and Prevention's (CDC) National Healthcare Safety Network (NHSN) Team partnered with the Veterans Affairs (VA) Informatics, Decision-Enhancement and Analytic Sciences (IDEAS 2.0) Center at the VA Salt Lake City Health Care System to create an Antimicrobial Use (AU) synthetic data set (SDS) and a vendor software validation process. NHSN will require all vendor systems electronically submitting AU data to NHSN be validated by January 2021 using the AU SDS.

The panel will provide an overview of the AU SDS and validation process along with a discussion of challenges faced including lessons learned during the implementation of this unique validation effort for NHSN data. Panelists will speak about the motivation, insights and methods behind the AU SDS and the validation process. Additionally, two vendors that have successfully completed the AU SDS validation process will share their experiences completing the validation process.

https://www.amia.org/summit2021/panels





AUR Vendors

The CDC's National Healthcare Safety Network (NHSN) Antimicrobial Use and Resistance (AUR) Module provides a mechanism for facilities to report antimicrobial use and/or resistance data. The following vendors have expressed interest in providing services and software that will allow participating in the AUR Module through direct reporting. Click HERE to download a copy.

Membership gives you more

- Access exclusive opportunities
- · Connect with colleagues
- Attend networking events

JOIN TODAY

Vendor Name	Vendor Contact	Contact E-mail/URL	Reporting Antimicrobial Use	Reporting Antimicrobial Resistance
Asolva, Inc.	Chun Wong	cwong@asolva.com	Yes	Yes

Partner Opportunity

Consulting revenue

- Develop data interface
- Local infrastructure setup
- Technical liaison
- Reports development

Co-marketing

- Leverage Asolva references
- Asolva assists with sales cycle

Training and support

- Implementation toolkit
- Remote support